These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36817315)

  • 1. Criteria for progressive fibrotic hypersensitivity pneumonitis in a Portuguese patient cohort.
    Seixas E; Ferreira M; Serra P; Aguiar R; Cunha I; Ferreira PG
    Afr J Thorac Crit Care Med; 2022; 28(4):. PubMed ID: 36817315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life prevalence of progressive fibrosing interstitial lung diseases.
    Gagliardi M; Berg DV; Heylen CE; Koenig S; Hoton D; Tamirou F; Pieters T; Ghaye B; Froidure A
    Sci Rep; 2021 Dec; 11(1):23988. PubMed ID: 34907290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
    Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
    Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
    Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
    Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of Transbronchial Lung Cryobiopsy When Starting Antifibrotic Treatment and Predicting Progressive Fibrosing Interstitial Lung Disease: Descriptive Research.
    Takatsuka M; Yamakawa H; Takemura T; Sato S; Ohta H; Kusano K; Oba T; Kawabe R; Akasaka K; Sasaki H; Amano M; Araya J; Matsushima H
    Clin Respir J; 2024 Jul; 18(7):e13809. PubMed ID: 39013830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung function trajectory in progressive fibrosing interstitial lung disease.
    Oldham JM; Lee CT; Wu Z; Bowman WS; Pugashetti JV; Dao N; Tonkin J; Seede H; Echt G; Adegunsoye A; Chua F; Maher TM; Garcia CK; Strek ME; Newton CA; Molyneaux PL
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34737223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derivation and validation of a prediction model for histopathologic fibrotic hypersensitivity pneumonitis.
    De Giacomi F; White D; Decker PA; Vaszar LT; Sandbo N; Lee AS; Ryu JH; Moua T
    Respir Med; 2021 Oct; 187():106598. PubMed ID: 34481307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reticulation pattern without honeycombing on high-resolution CT is associated with the risk of disease progression in interstitial lung diseases.
    Mononen M; Saari E; Hasala H; Kettunen HP; Suoranta S; Nurmi H; Kärkkäinen M; Selander T; Randell J; Laurikka J; Uibu T; Koskela H; Kaarteenaho R; Purokivi M
    BMC Pulm Med; 2022 Aug; 22(1):313. PubMed ID: 35965320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Features of transbronchial lung cryobiopsy-diagnosed fibrotic hypersensitivity pneumonitis.
    Zhan X; Du Y; Luo J; Que Y; Hu C; Xu L; Wang Z; Wu Y; Jin M; Zheng C; Gao Y; Chang C; Li H; Tong Z; Xu G
    Clin Respir J; 2023 Jan; 17(1):50-58. PubMed ID: 36397265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome.
    Kwon BS; Choe J; Chae EJ; Hwang HS; Kim YG; Song JW
    Respir Res; 2021 Oct; 22(1):282. PubMed ID: 34719401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
    Maher TM; Brown KK; Kreuter M; Devaraj A; Walsh SLF; Lancaster LH; Belloli EA; Padilla M; Behr J; Goeldner RG; Tetzlaff K; Schlenker-Herceg R; Flaherty KR;
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34210788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis, course and management of hypersensitivity pneumonitis.
    Hamblin M; Prosch H; Vašáková M
    Eur Respir Rev; 2022 Mar; 31(163):. PubMed ID: 35140104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Progression and Mortality in Patients with Chronic Hypersensitivity Pneumonitis: Retrospective Analysis of Registry of Fibrosing Interstitial Lung Diseases.
    Trushenko NV; Suvorova OA; Pershina ES; Nekludova GV; Chikina SY; Levina IA; Chernyaev AL; Samsonova MV; Tyurin IE; Mustafina MK; Yaroshetskiy AI; Nadtochiy NB; Merzhoeva ZM; Proshkina AA; Avdeev SN
    Life (Basel); 2023 Feb; 13(2):. PubMed ID: 36836825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial.
    Inoue Y; Kitamura H; Okamoto M; Ogura T; Nishioka Y; Kuwana M; Taniguchi A; Ito T; Rohr KB; Suda T
    Respir Investig; 2024 Jul; 62(4):589-596. PubMed ID: 38692040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries.
    Hilberg O; Hoffmann-Vold AM; Smith V; Bouros D; Kilpeläinen M; Guiot J; Morais A; Clemente S; Daniil Z; Papakosta D; Fretheim H; Neves S; Alfaro TM; Antoniou KM; Valveny N; Asijee G; Soulard S; Wuyts W
    ERJ Open Res; 2022 Jan; 8(1):. PubMed ID: 35083316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian Study.
    Sebastiani M; Venerito V; Laurino E; Gentileschi S; Atzeni F; Canofari C; Andrisani D; Cassone G; Lavista M; D'Alessandro F; Vacchi C; Scardapane A; Frediani B; Cazzato M; Salvarani C; Iannone F; Manfredi A
    J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and Lung Function Changes in Hypersensitivity Pneumonitis According to Radiological Phenotypes Compared With Idiopathic Pulmonary Fibrosis.
    Juliá-Serdá G; Navarro-Esteva J; Doreste-Salgado L; Véliz-Flores I; Pestana-Santana R; González-Martín JM; Rodríguez-de Castro F
    Cureus; 2024 Mar; 16(3):e57307. PubMed ID: 38690457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Overview of Progressive Fibrotic Interstitial Lung Disease.
    Case AH
    Front Med (Lausanne); 2022; 9():858339. PubMed ID: 35372405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.